Billionaire Jim Simons’ Top 5 Stock Picks

In this article, we discuss billionaire Jim Simons’ top 5 stock picks. For Simons’ investment philosophy and his comments on certain stocks please see Billionaire Jim Simons’ Top 10 Stock Picks.

5. Bristol-Myers Squibb Company (NYSE: BMY)

Value: $1,146,353,000
Percent of Jim Simons’ 13F Portfolio: 1.24%
Number of Hedge Fund Holders: 131

New York-based Bristol-Myers Squibb is one of the most famous biopharmaceutical companies in the world, offering treatments for various diseases, including viruses, HIV, cancer, heart and autoimmune diseases. The  National Institutes of Health (NIH) recently started evaluating Bristol Myers Squibb’s and Pfizer’s (NYSE:PFE) blood-thinning treatment Eliquis for patients who experience blood clotting after contracting COVID-19.

With a dividend yield of over 3%, BMY is one of the 10 best healthcare dividend stocks.

The stock is up about 4% over the last 12 months.

With a $2.07 billion stake in BMY, Warren Buffett’s Berkshire Hathaway owns 2.4 million shares of the company as of the end of the fourth quarter of 2020. Our database shows that 131 hedge funds held stakes in BMY at the end of the fourth quarter, versus 124 funds at the end of the third quarter.

In their Q4 2020 Investor Letter, Wedgewood Partners highlighted a few stocks and Bristol Myers Squibb Co (NYSE:BMY) is one of them.

Here is what Wedgewood Partners said:

“Bristol-Myers Squibb recently reported accelerating sales as much of the medical services industry returned to work. The Company continues to expect double-digit earnings growth over the next few years, driven by existing drugs, in addition to a broad pipeline of new drugs and indications. While the market remains fixated on a couple of patent expirations that could occur over the next several years, we think this is well-known at this point, yet the market still undervalues a couple of key acquisitions the Company has made in the past few years, particularly Celgene, which was acquired for a song.”